Efficacy of lentivirus‐mediated gene therapy in an Omenn syndrome recombination‐activating gene 2 mouse model is not hindered by inflammation and immune dysregulation

[1]  F. Rieux-Laucat,et al.  Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies , 2017, The Journal of allergy and clinical immunology.

[2]  M. Porteus,et al.  The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation , 2017, Current opinion in hematology.

[3]  David A. Williams,et al.  Evolving Gene Therapy in Primary Immunodeficiency. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Claudio Mussolino,et al.  Refining strategies to translate genome editing to the clinic , 2017, Nature Medicine.

[5]  C. Cancrini,et al.  Late‐onset combined immune deficiency due to LIGIV mutations in a 12‐year‐old patient , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[6]  D. Kohn,et al.  New frontiers in the therapy of primary immunodeficiency: From gene addition to gene editing. , 2017, The Journal of allergy and clinical immunology.

[7]  L. Notarangelo,et al.  Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects afte , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  Pachai Natarajan,et al.  CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease , 2017, Science Translational Medicine.

[9]  E. Husebye,et al.  Autoimmune regulator and self‐tolerance – molecular and clinical aspects , 2016, Immunological reviews.

[10]  L. Notarangelo,et al.  Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency , 2016, Science Translational Medicine.

[11]  A. Thrasher,et al.  Treating Immunodeficiency through HSC Gene Therapy. , 2016, Trends in molecular medicine.

[12]  L. Notarangelo,et al.  Human RAG mutations: biochemistry and clinical implications , 2016, Nature Reviews Immunology.

[13]  F. Candotti Advances of gene therapy for primary immunodeficiencies , 2016, F1000Research.

[14]  G. Pesole,et al.  Intestinal microbiota sustains inflammation and autoimmunity induced by hypomorphic RAG defects , 2016, The Journal of experimental medicine.

[15]  S. Hacein-Bey-Abina,et al.  Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand? , 2016, Human gene therapy.

[16]  T. Kodama,et al.  Fezf2 Orchestrates a Thymic Program of Self-Antigen Expression for Immune Tolerance , 2015, Cell.

[17]  J. B. Oliveira,et al.  Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. , 2015, The Journal of clinical investigation.

[18]  D. Trono,et al.  Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  O. Ohara,et al.  RAG1 Deficiency May Present Clinically as Selective IgA Deficiency , 2015, Journal of Clinical Immunology.

[20]  J. McElwee,et al.  Identification of Patients with RAG Mutations Previously Diagnosed with Common Variable Immunodeficiency Disorders , 2015, Journal of Clinical Immunology.

[21]  L. Notarangelo,et al.  A hypomorphic recombination-activating gene 1 (RAG1) mutation resulting in a phenotype resembling common variable immunodeficiency. , 2014, The Journal of allergy and clinical immunology.

[22]  M. Seidel Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. , 2014, Blood.

[23]  L. Notarangelo,et al.  Transplantation outcomes for severe combined immunodeficiency, 2000-2009. , 2014, The New England journal of medicine.

[24]  L. Notarangelo,et al.  Rag Defects and Thymic Stroma: Lessons from Animal Models , 2014, Front. Immunol..

[25]  M. van der Burg,et al.  Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells , 2014, Nature.

[26]  R. Sarwari,et al.  Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome. , 2014, The Journal of allergy and clinical immunology.

[27]  U. Pannicke,et al.  SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. , 2014, Blood.

[28]  S. Mantero,et al.  Hypomorphic mutation in the RAG2 gene affects dendritic cell distribution and migration , 2013, Journal of leukocyte biology.

[29]  E. Haddad,et al.  B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment? , 2013, The Journal of allergy and clinical immunology.

[30]  Aaron R Cooper,et al.  Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. , 2012, Blood.

[31]  G. Wagemaker,et al.  Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  Fabio Grassi,et al.  Anti-CD3ε mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications. , 2012, Blood.

[33]  Y. Takeuchi,et al.  Safer, Silencing-Resistant Lentiviral Vectors: Optimization of the Ubiquitous Chromatin-Opening Element through Elimination of Aberrant Splicing , 2012, Journal of Virology.

[34]  D. Schatz,et al.  V(D)J recombination: mechanisms of initiation. , 2011, Annual review of genetics.

[35]  A. Schambach,et al.  Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer , 2011, Leukemia.

[36]  L. Naldini,et al.  Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome. , 2011, The Journal of allergy and clinical immunology.

[37]  A. Fischer,et al.  Immune deficiencies , infection , and systemic immune disorders Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe : Entering a new century , do we do better ? , 2010 .

[38]  F. Alt,et al.  Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency , 2010, The Journal of experimental medicine.

[39]  M. van der Burg,et al.  Homeostatic expansion of autoreactive immunoglobulin-secreting cells in the Rag2 mouse model of Omenn syndrome , 2010, The Journal of experimental medicine.

[40]  R. Buckley B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review. , 2010, The Journal of allergy and clinical immunology.

[41]  Alessandro Aiuti,et al.  Gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2009, The New England journal of medicine.

[42]  Y. Lokhnygina,et al.  Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. , 2009, The Journal of pediatrics.

[43]  M. Cancro Signalling crosstalk in B cells: managing worth and need , 2009, Nature Reviews Immunology.

[44]  L. Notarangelo,et al.  Early defects in human T-cell development severely affect distribution and maturation of thymic stromal cells: possible implications for the pathophysiology of Omenn syndrome. , 2009, Blood.

[45]  K. Siminovitch,et al.  Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  A. Fischer,et al.  Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. , 2009, Blood.

[47]  L. Notarangelo,et al.  A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome. , 2007, The Journal of clinical investigation.

[48]  N. Olsen,et al.  Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes , 2006, Clinical and experimental immunology.

[49]  D. Allman,et al.  Characterization of marginal zone B cell precursors , 2005, The Journal of experimental medicine.

[50]  A. Fischer,et al.  AIRE deficiency in thymus of 2 patients with Omenn syndrome. , 2005, The Journal of clinical investigation.

[51]  A. Fischer,et al.  Gene therapy of RAG-2-/- mice: sustained correction of the immunodeficiency. , 2002, Blood.

[52]  J. Puck,et al.  Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. , 2002, Blood.

[53]  K. Rajewsky,et al.  Homeostasis of Peripheral B Cells in the Absence of B Cell Influx from the Bone Marrow , 2001, The Journal of experimental medicine.

[54]  A. Fischer,et al.  Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. , 2001, Blood.

[55]  Sandro Santagata,et al.  Partial V(D)J Recombination Activity Leads to Omenn Syndrome , 1998, Cell.

[56]  G. Omenn FAMILIAL RETICULOENDOTHELIOSIS WITH EOSINOPHILIA. , 1965, The New England journal of medicine.

[57]  R. Buckley,et al.  Post-Transplantation B Cell Function in Different Molecular Types of SCID , 2012, Journal of Clinical Immunology.